Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

OBJECTIVE: To report on safety and effectiveness of subcutaneous cladribine (Litak(®)) in multiple sclerosis (MS) patients. METHODS: Litak(®) was offered to MS-patients irrespective of disease course. Litak(®) 10 mg was administered for 3–4 days during week 1. Based on lymphocyte count at week 4, pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen-Philbey, Kimberley, De Trane, Stefania, Mao, Zhifeng, Álvarez-González, Cesar, Mathews, Joela, MacDougall, Amy, Stennett, Andrea, Zhou, Xia, Yildiz, Ozlem, Adams, Ashok, Bianchi, Lucia, Blain, Camilla, Chapman, Christine, Chung, Karen, Constantinescu, Cris S, Dalton, Catherine, Farrell, Rachel A, Fisniku, Leonora, Ford, Helen, Gran, Bruno, Hobart, Jeremy, Khaleeli, Zhaleh, Mattoscio, Miriam, Pavitt, Sue, Pearson, Owen, Peruzzotti-Jametti, Luca, Scalfari, Antonio, Sharrack, Basil, Silber, Eli, Tallantyre, Emma C, Webb, Stewart, Turner, Benjamin P, Marta, Monica, Gnanapavan, Sharmilee, Juliusson, Gunnar, Giovannoni, Gavin, Baker, David, Schmierer, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842147/
https://www.ncbi.nlm.nih.gov/pubmed/35173808
http://dx.doi.org/10.1177/17562864211057661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842147/
https://www.ncbi.nlm.nih.gov/pubmed/35173808
http://dx.doi.org/10.1177/17562864211057661

Ejemplares similares